Castor, a leading provider of decentralized and hybrid clinical trial solutions, announced the official launch of its CRO Partnership program. Designed to support clinical research organizations (CROs), the program provides the technical capabilities, operational training and commercial resources required to successfully deliver traditional, hybrid and decentralized clinical programs for trial sponsors.
“Castor allows us to add value to our service offerings and deliver innovative technology solutions with minimal upfront investment,” said Kathleen Marshall, President and Founder of MAXIS LLC. “As a partner, we’ve been able to reduce time spent building and managing studies, streamline data collection, increase access and reduce the burden on sites and patients.”
The success of clinical trials relies heavily on the eClinical solutions that support them, making it imperative to implement a flexible, technology-enabled approach. Castor’s modular eClinical platform with self-service functionality is lightweight, easy to use, easy to deploy and easily integrated with established systems. Castor’s out-of-the-box solutions reduce the number of tools needed to execute a clinical trial while also minimizing the need for add-on services when designing proposals for sponsors. As a Castor partner, CROs can deliver studies of varying complexity for more sponsors, with the necessary flexibility and speed to quickly adapt, without disrupted timelines or expanded budgets.
“We look forward to launching our CRO partnership program, as our platform offers unprecedented scalability, enabling our CRO partners to run patient centric trials as their core business, instead of in a pilot setting,” said Derk Arts, CEO & Founder, Castor. “Decentralized clinical trials offer increased patient engagement, convenience, shorter trial times, and allows for a more diverse representation of patients in studies compared to conventional trials.”
Further accelerated by the COVID-19 pandemic, regulators and trial sponsors emphasize the need for faster, more accessible clinical trials to improve data quality and equitable health outcomes. According to a recent industry survey, an estimated 50% of clinical trials will be hybrid or decentralized by 2024. Castor’s modular DCT platform with integrated EDC allows CROs to streamline traditional approaches and offers a pathway to manage hybrid and DCTs successfully. With increased access to Castor’s professional services team and named customer success manager (CSM), CRO partners receive the technical guidance and operational support to successfully scale their DCT capabilities using a modern, easy-to-learn platform.
Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest-rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug-and-play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, eConsent, and real-world data capture. Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security, and reusability of data for researchers worldwide.